TG Therapeutics reports Q3 EPS 73c, consensus 12c

Reports Q3 revenue $165.8M, consensus $46.56M. Michael Weiss, the Company’s Chairman and Chief Executive Officer, stated, “The team has executed very well in the third quarter, making significant progress on our corporate goals and continuing to build a solid foundation for the BRIUMVI launch. We showed strong net quarterly revenue of approximately $166 million, including an upfront milestone payment from our ex-U.S. partner, Neuraxpharm, as well as $25.1 million in BRIUMVI net sales in the U.S., which again exceeded our expectations.” Mr. Weiss continued, “The adoption of BRIUMVI from both healthcare providers and centers continues to grow, which I believe positions us to close out the year on a positive note and I am excited for 2024 and for the future of BRIUMVI and TG.”